Acute respiratory distress syndrome (ARDS) is characterized by diffuse pulmonary edema that impairs gas exchange and leads to hypoxemia. ARDS can be caused by direct or indirect lung injury from a variety of common conditions including sepsis, pneumonia, trauma, acid aspiration, ischemia-reperfusion, chemical inhalation, and overdistension by mechanical ventilation. Due to its diverse etiology, extremely high hospital case-fatality rates, and poor long-term prognosis, the syndrome has increasingly been recognized by the NIH and biomedical investigators as an important public health concern. Unfortunately, options for treating ARDS remain extremely limited. The only proven methods for enhancing survival are protective, low-tidal-volume mechanical ventilation and prone positioning, both of which are implemented once a patient is in poor enough condition to require intubation. As such, the last decade has witnessed a strong effort among researchers to develop therapies that can prevent lung injury from progressing to ARDS, a trend that has been buttressed by the establishment by the NIH of the Prevention and Early Treatment of Acute Lung Injury (PETAL) multi-site network of clinical trials. A number of promising drugs for ARDS prevention are in the early translational stages of research, including transient receptor potential vanilloid 4 (TRPV4) inhibitors, which block calcium channels whose activation is an important facilitator of pulmonary endothelial hyperpermeability and edema. Administration of these preventive ARDS therapeutics to patients with optimal sensitivity and specificity requires the corollary development of diagnostic tools that can identify individuals who are particularly at risk of progressing to severe lung injury before this progression occurs. In response to this need and in line with the guiding focus of this RFA, the proposed project will develop a molecular probe capable of detecting the early metabolic signs of lung injury before edema develops. Through injecting hyperpolarized (HP) 13C-labeled pyruvate and imaging the subject with magnetic resonance (MR), we are able to track its real-time conversion to lactate and bicarbonate in the lung. Decreased conversion to bicarbonate and increased conversion to lactate indicate mitochondrial dysfunction and upregulated glycolysis, respectively, which have been associated with the endothelial hyperpermeability that allows formation of edema. The first fundamental task of this project will be to demonstrate that HP 13C pyruvate can non-invasively detect lung injury in rodent models before conventional clinical metrics (chest x-ray/computed tomography [CT] to identify edema and alveolar blood gas testing to identify hypoxemia). Second, we will investigate the bioenergetics effects of TRPV4 inhibitors using 13C pyruvate, thereby gaining an idea of how blockage of the TRPV4 channel affects the metabolic characteristics that our probe is measuring. Third, we will assess whether early detection of lung injury pathogenesis using HP 13C MRI and subsequent treatment with a TRPV4 inhibitor generates better outcomes than when the same TRPV4 inhibitor is administered when injury is determined via conventional techniques. Finally, we will evaluate the ability of HP 13C pyruvate to predict endpoints in extracorporeal, perfused human lungs treated with a TRPV4 inhibitor in order to assess the performance of the probe in a human tissue model; the findings of this aim will also have high relevance for the prediction and prevention of lung injury in lung transplant patients.

Public Health Relevance

This project seeks to develop a hyperpolarized 13C magnetic resonance imaging (HP 13C MRI) probe capable of non-invasively detecting the early signs of lung injury before it progresses to acute respiratory distress syndrome (ARDS). While ARDS has very poor short- and long-term outcomes, recent research has identified a number of drugs that may be effective in preventing it. Early diagnosis of lung injury using molecular imaging will allow these drugs to be administered to at-risk patients before this injury becomes severe.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL139066-04
Application #
9963343
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Zhou, Guofei
Project Start
2017-09-01
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
4
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Xin, Yi; Cereda, Maurizio; Hamedani, Hooman et al. (2018) Unstable Inflation Causing Injury. Insight from Prone Position and Paired Computed Tomography Scans. Am J Respir Crit Care Med 198:197-207